Business Context and Reporting Period
This Form 8-K was filed by Aerovate Therapeutics, Inc. (not Jade Biosciences, Inc.) on August 12, 2021, reporting events occurring on August 6, 2021. The registrant is an emerging growth company incorporated in Delaware, with its principal executive offices in Boston, Massachusetts. The filing discloses the entry into a material definitive agreement regarding new corporate headquarters.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, or debt metrics. It focuses exclusively on a new lease obligation.
- Lease Term: 36 months, with an option to extend for an additional 3 years.
- Lease Area: Approximately 5,003 square feet.
- Base Rent: $43.00 per rentable square foot per year in the first year.
- Rent Escalation: Scheduled annual increases of $1.00 per rentable square foot.
- Rent Commencement: Expected to begin on the 121st day following delivery of the premises (anticipated around September 1, 2021).
Material Changes
The Company entered into a lease with PDM 930 Unit, LLC for premises at 930 Winter Street, Waltham, Massachusetts, which will serve as its new corporate headquarters. This represents a new direct financial obligation under an off-balance sheet arrangement.
Outlook, Risks, and Management Commentary
Management has not provided financial guidance or commentary on operational outlook in this specific filing. The primary risk disclosed is the creation of a fixed financial obligation for rent payments commencing in late 2021. The filing notes that the rent obligation is contingent upon the Landlord delivering the premises with certain improvements.
Investor Verification Checklist
- Verify the exact delivery date of the premises to confirm the Rent Commencement Date.
- Review the full text of the Lease (Exhibit 10.1) for termination clauses, additional operating expenses, or capital improvement obligations not summarized here.
- Confirm the Company's current cash position to ensure it can meet the new rent obligations starting in September 2021.
- Note the discrepancy in the request metadata: The filing is for Aerovate Therapeutics, Inc., not Jade Biosciences, Inc.